Title: Factor associated with global mortality in COPD between 2006 and 2011: French claims data

Dr. Laurent 7505 Laforest laurent.laforest@univ-lyon1.fr MD 1, Mr. Cheikh 7504 Tamberou Cheikh.Tamberou@univ-lyon1.fr 1, Ms. Marine 7506 Ginoux marine.ginoux@univ-lyon1.fr 1, Mr. Chu-Philippe 7507 Ya chu-philippe.ya@univ-lyon1.fr 1, Prof. Gilles 7508 Devouassoux gilles.devouassoux@chu-lyon.fr MD 2, Prof. Nicolas 7514 Roche nicolas.roche@htd.aphp.fr MD 3, Prof. Christos 7527 Chouaid christos.chouaid@sat.aphp.fr MD 4 and Dr. Eric 7528 Van Ganse eric.van-ganse@univ-lyon1.fr MD 1,2 1 Pharmacoépidemiology, Lyon University Hospital UMR 5558 CNRS - Claude Bernard University, Lyon, France ; 2 Respiratory Medicine, Croix-Rousse University Hospital, Lyon, France ; 3 Respiratory and Intensive Care Medicine & University Paris Descartes, Hôtel-Dieu Hospital, Paris, France and 4 Respiratory Medicine, Creteil University Hospital, Creteil, France .

Body: Background: A good understanding of prognostic factors of death in COPD may contribute to improve disease management. The role of patient and management-related factors during a baseline period on global mortality during the following years was investigated in COPD. Methods: A cohort of patients aged≥45, with documented follow-up and ≥3 dispensations in 2005 of a same drug-class were selected in French Claims data. Drug classes were long-acting beta agonists, short-acting beta agonists (SABAs), short-acting muscarinic antagonists (SAMAs), xanthines, and SAMA/SABA fixed combinations. Cox multivariate models were used to predict global 2006-2011 mortality. Analyzed co-factors were age, gender, dispensing level inhaled bronchodilator therapy in 2005, free-access-to-care status, long-term-disease status (diabetes, respiratory, cardiovascular, tumoral, and mental diseases) and COPD-related hospitalization in 2005 (1-10, >10 days). Results: The mean annual death rate between 2006 and 2011 of the 4,800 patients (mean age 66, 50% women) was 4.6%. The strongest predicting factors was duration of COPD-related hospitalizations in 2005 (HR=2.0 and 2.3 for hospital stays of 1-10 days and >10 days, respectively), long-term disease status of cancer (HR=1.8), cardiovascular diseases (HR=1.3) and male gender (HR=1.7), p<0.0001 for all. Significant effects were also observed with long-term disease status for mental disorders (p=0.0004), severe respiratory condition (p=0.003) and diabetes (p=0.02). Conclusions: In this cohort of COPD patients, severe exacerbations for COPD in 2005 were the most prominent risk factor of death between 2006 and 2011. Comorbidities also markedly impacted COPD global mortality.